The Federal Circuit reversed the District of Delaware’s decision to invalidate Orexo’s opioid treatment patent as obvious because obviousness was not proved by clear and convincing evidence. Specifically, the Court pointed to the absence of a teaching in the prior art that citric acid could serve as a carrier particle for the drug agonist. The Court also noted that the lower court improperly discounted evidence of objective indicia of nonobviousness.
The post Federal Circuit Reverses, Finds Opioid Addiction Treatment Patent Nonobvious appeared first on IPWatchdog.com | Patents & Patent Law.
+1 732-444-6303
